Positive Results Published from First Bioabsorbable Drug-Eluting Stent Trial
Data published in The Lancet from the world’s first clinical trial of Abbott’s fully bioabsorbable drug-eluting stent demonstrated excellent clinical safety in patients with coronary artery disease. The one-year results demonstrated no stent thrombosis, no retreatment of diseased lesions, and a low rate of major adverse cardiac events (MACE) in 30 patients. Our stent also demonstrated 100 percent procedural success and 94 percent device success in the trial.
Abbott is the only company with a fully bioabsorbable drug-eluting coronary stent in clinical trials. Our everolimus-eluting coronary stent is made of polylactic acid, a proven biocompatible material that is commonly used in medical implants such as dissolvable sutures. As with a metallic stent, our bioabsorbable stent is designed to restore blood flow in clogged coronary arteries, and to provide mechanical support until the blood vessel heals. Unlike a metallic stent, however, a bioabsorbable stent is designed to be slowly metabolized by the body and completely absorbed over time.
Additional Information
- Press release: March 13, 2008
The Lancet Publishes Results from World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent - View an animation on how the stent works.
